---
title: "Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer: Clinical trials questions"
description: "Clinical trials questions on Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results and Interpreting study results. Questions: Who was eligible for the KEYTRUDA KEYNOTE-522 trial? What chemotherapy was given with KEYTRUDA in KEYNOTE-522? Does the KEYTRUDA benefit come from treatment before or after surgery (KEYNOTE-522)? What were baseline characteristics in the KEYTRUDA KEYNOTE-522 trial? 4 further questions follow. 8 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/clinical-trials"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer: Clinical trials questions

Manufacturer: Merck Sharp & Dohme LLC  
Prescribing information: [Keytruda](https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf)

## Clinical trials

<a id="keytruda-early-tnbc-eligibility"></a>

### Who was eligible for the KEYTRUDA KEYNOTE-522 trial?

> “1,174 patients with newly diagnosed, previously untreated high-risk early-stage TNBC were evaluated in a randomized, multicenter, double-blind, placebo-controlled trial
> Patient Eligibility
>
> Key Inclusion Criteria
>
> Patients with newly diagnosed, previously untreated high-risk early-stage TNBC
> Patients were enrolled regardless of tumor PD-L1 expression
> Tumor size >1 cm but ≤2 cm in diameter with nodal involvement or tumor size >2 cm in diameter regardless of nodal involvement
>
> Key Exclusion Criteria
>
> Patients with active autoimmune disease that required systemic therapy within 2 years of treatment
> Patients with a medical condition that required immunosuppression”

Source: [KEYTRUDA: KEYNOTE-522 - Study Design & Clinical Findings, captured 2026-11-08](https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/#:~:text=1%2C174%20patients%20with%20newly%20diagnosed%2C,medical%20condition%20that%20required%20immunosuppression)

<a id="keytruda-kn522-regimen"></a>

### What chemotherapy was given with KEYTRUDA in KEYNOTE-522?

> “Study Arms
> KEYTRUDA (n=784)
> Neoadjuvant Regimen (cycles 1–4)
> KEYTRUDA 200 mg Q3W on day 1
> Carboplatin (AUC 5 mg/mL/min Q3W on day 1 OR AUC 1.5 mg/mL/min (weekly) on days 1, 8, and 15)
> Paclitaxel (80 mg/m<sup>2</sup> on days 1, 8, and 15)
>
>
>
>
> Neoadjuvant Regimen (cycles 5–8)
> KEYTRUDA 200 mg Q3W on day 1
> Doxorubicin (60 mg/m<sup>2</sup> Q3W) on day 1 OR Epirubicin (90 mg/m<sup>2</sup> Q3W) on day 1
> Cyclophosphamide (600 mg/m<sup>2</sup> Q3W) on day 1
>
>
>
>
> Surgery
>
>
>
>
> Adjuvant Regimen (9 cycles)
> KEYTRUDA 200 mg Q3W on day 1
> Placebo (n=390)
> Neoadjuvant Regimen (cycles 1–4)
> Placebo Q3W on day 1
> Carboplatin (AUC 5 mg/mL/min Q3W on day 1 OR AUC 1.5 mg/mL/min (weekly) on days 1, 8, and 15)
> Paclitaxel (80 mg/m<sup>2</sup> on days 1, 8, and 15)
>
>
>
>
> Neoadjuvant Regimen (cycles 5–8)
> Placebo Q3W on day 1
> Doxorubicin (60 mg/m<sup>2</sup> Q3W) on day 1 OR Epirubicin (90 mg/m<sup>2</sup> Q3W) on day 1
> Cyclophosphamide (600 mg/m<sup>2</sup> Q3W) on day 1
>
>
>
>
> Surgery
>
>
>
>
> Adjuvant Regimen (9 cycles)
> Placebo Q3W on day 1”

Source: [KEYTRUDA: KEYNOTE-522 - Study Design & Clinical Findings, captured 2026-11-08](https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/#:~:text=Study%20Arms,Placebo%20Q3W%20on%20day%201)

> “All study medications were administered intravenously.”

Source: [KEYTRUDA: KEYNOTE-522 - Study Design & Clinical Findings, captured 2026-11-08](https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/#:~:text=All%20study%20medications%20were%20administered%20intravenously.)

<a id="keytruda-phase-contribution"></a>

### Does the KEYTRUDA benefit come from treatment before or after surgery (KEYNOTE-522)?

> “The trial was not designed to isolate the effect of KEYTRUDA in each phase (neoadjuvant or adjuvant) of treatment.”

Source: [KEYTRUDA: KEYNOTE-522 - Study Design & Clinical Findings, captured 2026-11-08](https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/#:~:text=The%20trial%20was%20not%20designed,%28neoadjuvant%20or%20adjuvant%29%20of%20treatment.)

<a id="keytruda-kn522-baseline"></a>

### What were baseline characteristics in the KEYTRUDA KEYNOTE-522 trial?

> “Baseline Characteristics (N=1,174)
>
> Median age, years (range): 49 (22–80)
> Aged ≥65 years: 11%
> Female: 99.9%
> Race
> White: 64%
> Asian: 20%
> Black: 4.5%
> American Indian or Alaska Native: 1.8%
> ECOG PS
> 0: 87%
> 1: 13%
> Menopausal status
> Pre-menopausal: 56%
> Post-menopausal: 44%
> Primary tumor classification
> T1: 7%
> T2: 68%
> T3: 19%
> T4: 7%
> Nodal involvement
> N0: 49%
> N1: 40%
> N2: 11%
> N3: 0.2%
> Overall disease stage
> II: 75%
> III: 25%”

Source: [KEYTRUDA: KEYNOTE-522 - Study Design & Clinical Findings, captured 2026-11-08](https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/#:~:text=Baseline%20Characteristics%20%28N%3D1%2C174%29,III%3A%2025%25)

## Study results

<a id="keytruda-pcr-results"></a>

### How often did KEYTRUDA plus chemotherapy leave no invasive cancer at surgery (KEYNOTE-522)?

> “pCR was defined as absence of invasive cancer in the breast and lymph nodes (ypT0/Tis ypN0) and was assessed by the blinded local pathologist at the time of definitive surgery.”

Source: [KEYTRUDA: KEYNOTE-522 - Study Design & Clinical Findings, captured 2026-11-08](https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/#:~:text=pCR%20was%20defined%20as%20absence,the%20time%20of%20definitive%20surgery.)

> “Pathological Complete Response (pCR) Rate
> pCR With KEYTRUDA + Chemotherapy<sup>c</sup> vs Placebo + Chemotherapy<sup>c</sup> in the Neoadjuvant Setting
> pCR Rate (ypT0/Tis ypN0)<sup>d</sup>
> pCR
> 63.0%
> (95% CI, 59.5–66.4)
> (n/N=494/784)
> KEYTRUDA + chemotherapy<sup>c</sup>
> vs
> pCR
> 55.6%
> (95% CI, 50.6–60.6)
> (n/N=217/390)
> Placebo + chemotherapy<sup>c</sup>
> Estimated treatment difference: ~7.5% (95% CI, 1.6–13.4)<sup>e,f</sup> with KEYTRUDA + chemotherapy<sup>c</sup> vs placebo + chemotherapy<sup>c</sup>
> c.
> Carboplatin/paclitaxel followed by AC or EC.
> d.
> Based on the entire intention-to-treat population N=1,174 patients.
> e.
> Based on a prespecified pCR interim analysis in patients (n=602), the pCR rate difference was statistically significant (P=0.00055 compared to a significance level of 0.003).
> f.
> Based on Miettinen and Nurminen method stratified by nodal status, tumor size, and choice of carboplatin.
> CI = confidence interval; AC = doxorubicin + cyclophosphamide; EC = epirubicin + cyclophosphamide.”

Source: [KEYTRUDA: KEYNOTE-522 - Study Design & Clinical Findings, captured 2026-11-08](https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/#:~:text=pCR%20With%20KEYTRUDA,EC%20%3D%20epirubicin%20%2B%20cyclophosphamide.)

<a id="keytruda-efs-results"></a>

### What was KEYTRUDA event-free survival in KEYNOTE-522?

> “Superior EFS With KEYTRUDA + Chemotherapy<sup>g</sup>/KEYTRUDA vs Placebo + Chemotherapy<sup>g</sup>/Placebo at IA4”

Source: [KEYTRUDA: KEYNOTE-522 - Study Design & Clinical Findings, captured 2026-11-08](https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/#:~:text=Superior%20EFS%20With%20KEYTRUDA,at%20IA4)

> “37% reduction in the risk of an EFS event<sup>k</sup> with KEYTRUDA + chemotherapy<sup>g</sup>/KEYTRUDA vs placebo + chemotherapy<sup>g</sup>/placebo (HR<sup>h</sup>=0.63; 95% CI, 0.48–0.82; P<sup>i,j</sup>=0.00031)
> The number of patients with an event was 123/784 (16%) with KEYTRUDA + chemotherapy<sup>g</sup>/KEYTRUDA vs 93/390 (24%) with placebo + chemotherapy<sup>g</sup>/placebo
> g.
> Carboplatin/paclitaxel followed by AC or EC.
> h.
> HR based on stratified Cox regression model.
> i.
> P value based on a prespecified EFS interim analysis (compared to a significance level of 0.0052).
> j.
> P value based on log-rank test stratified by nodal status, tumor size, and choice of carboplatin.
> k.
> EFS was defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes definitive surgery, local or distant recurrence, second primary malignancy, or death due to any cause.
> HR = hazard ratio. IA4 = fourth interim analysis.”

Source: [KEYTRUDA: KEYNOTE-522 - Study Design & Clinical Findings, captured 2026-11-08](https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/#:~:text=37%25%20reduction%20in%20the%20risk,IA4%20%3D%20fourth%20interim%20analysis.)

<a id="keytruda-os-results"></a>

### Does KEYTRUDA with chemotherapy lower the risk of death in early-stage TNBC (KEYNOTE-522)?

> “Superior Overall Survival (OS) With KEYTRUDA + Chemotherapy<sup>l</sup>/KEYTRUDA vs Placebo + Chemotherapy<sup>l</sup>/Placebo at IA7<sup>3</sup>”

Source: [KEYTRUDA: KEYNOTE-522 - Study Design & Clinical Findings, captured 2026-11-08](https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/#:~:text=Superior%20Overall%20Survival%20%28OS%29%20With,at)

> “34% reduction in the risk of death with KEYTRUDA + chemotherapy<sup>l</sup>/KEYTRUDA vs placebo + chemotherapy<sup>l</sup>/placebo (HR<sup>m</sup>=0.66; 95% CI, 0.50–0.87; P<sup>n,o</sup>=0.00150)
> The number of patients with an event was 115/784 (15%) with KEYTRUDA + chemotherapy<sup>l</sup>/KEYTRUDA vs 85/390 (22%) with placebo + chemotherapy<sup>l</sup>/placebo
> l.
> Carboplatin/paclitaxel followed by AC or EC.
> m.
> Based on stratified Cox regression model.
> n.
> Based on log-rank test stratified by nodal status, tumor size, and choice of carboplatin.
> o.
> Based on prespecified OS interim analysis (compared to a significance level of 0.0050).
> IA7 = seventh interim analysis.”

Source: [KEYTRUDA: KEYNOTE-522 - Study Design & Clinical Findings, captured 2026-11-08](https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/#:~:text=34%25%20reduction%20in%20the%20risk,IA7%20%3D%20seventh%20interim%20analysis.)

## Interpreting study results

<a id="keytruda-subgroup-caution"></a>

### What are the limitations of KEYTRUDA KEYNOTE-522 survival subgroup results?

> “LIMITATIONS: KEYNOTE-522 was not powered to detect differences in the treatment effect in these subgroups, and no statistical testing was planned for this analysis; therefore, no conclusions can be drawn. Results from exploratory subgroup analyses should be interpreted with caution because of the modest patient numbers and potential imbalances in baseline characteristics within the subgroups.”

Source: [KEYTRUDA: KEYNOTE-522 - Study Design & Clinical Findings, captured 2026-11-08](https://www.keytrudahcp.com/efficacy/early-stage-triple-negative-breast-cancer/#:~:text=LIMITATIONS%3A,baseline%20characteristics%20within%20the%20subgroups.)

## Related pages
- [Medical information: Keytruda (pembrolizumab): High-risk early-stage triple-negative breast cancer](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/guidelines)
